Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2018

Open Access 01-12-2018 | Research

The clinical spectrum and genetic variability of limb-girdle muscular dystrophy in a cohort of Chinese patients

Authors: Liang Wang, Victor Wei Zhang, Shaoyuan Li, Huan Li, Yiming Sun, Jing Li, Yuling Zhu, Ruojie He, Jinfu Lin, Cheng Zhang

Published in: Orphanet Journal of Rare Diseases | Issue 1/2018

Login to get access

Abstract

Background

Limb-girdle muscular dystrophy (LGMD) is a commonly diagnosed hereditary muscular disorder, characterized by the progressive weakness of the limb-girdle muscles. Although the condition has been well-characterized, clinical and genetic heterogeneity can be observed in patients with LGMD. Here, we aimed to describe the clinical manifestations and genetic variability among a cohort of patients with LGMD in South China.

Results

We analyzed the clinical information, muscle magnetic resonance imaging (MRI) findings, and genetic results obtained from 30 patients (24 families) with clinically suspected LGMD. In 24 probands, 38 variants were found in total, of which 18 were shown to be novel. Among the 30 patients, the most common subtypes were dysferlinopathy in eight (26.67%), sarcoglycanopathies in eight [26.67%; LGMD 2C in three (10.00%), LGMD 2D in three (10.00%), and LGMD 2F in two (6.67%)], LGMD 2A in seven (23.33%), followed by LGMD 1B in three (10.00%), LGMD 2I in three (10.00%), and early onset recessive Emery-Dreifuss-like phenotype without cardiomyopathy in one (3.33%). Furthermore, we also observed novel clinical presentations for LGMD 1B, 2F, and 2I patients with hypermobility of the joints in the upper limbs, a LGMD 2F patient with delayed language development, and other manifestations. Moreover, distinct distributions of fatty infiltration in patients with LGMD 2A, dysferlinopathy, and the early onset recessive Emery-Dreifuss-like phenotype without cardiomyopathy were also observed based on muscle MRI results.

Conclusions

In this study, we expanded the clinical spectrum and genetic variability found in patients with LGMD, which provided additional insights into genotype and phenotype correlations in this disease.
Appendix
Available only for authorised users
Literature
1.
Mah JK, Korngut L, Fiest KM, Dykeman J, Day LJ, Pringsheim T, et al. A systematic review and meta-analysis on the epidemiology of the muscular dystrophies. Can J Neurol Sci. 2016;43:163–77.CrossRefPubMed
2.
3.
Deenen JC, Horlings CG, Verschuuren JJ, Verbeek AL, van Engelen BG. The epidemiology of neuromuscular disorders: a comprehensive overview of the literature. J Neuromuscul Dis. 2015;2:73–85.CrossRefPubMed
4.
Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 2014;24:482–91.CrossRefPubMed
5.
Magri F, Nigro V, Angelini C, Mongini T, Mora M, Moroni I, et al. The italian limb girdle muscular dystrophy registry: relative frequency, clinical features, and differential diagnosis. Muscle Nerve. 2017;55:55–68.CrossRefPubMed
6.
Sveen ML, Schwartz M, Vissing J. High prevalence and phenotype-genotype correlations of limb girdle muscular dystrophy type 2I in Denmark. Ann Neurol. 2006;59:808–15.CrossRefPubMed
7.
Bastian A, Mageriu V, Micu G, Manole E. The growing family of limb-girdle muscular dystrophies: old and newly identified members. Rom J Intern Med. 2015;53:13–24.CrossRefPubMed
8.
9.
Vissing J. Limb girdle muscular dystrophies: classification, clinical spectrum and emerging therapies. Curr Opin Neurol. 2016;29:635–41.CrossRefPubMed
10.
Straub V, Bertoli M. Where do we stand in trial readiness for autosomal recessive limb girdle muscular dystrophies? Neuromuscul Disord. 2016;26:111–25.CrossRefPubMed
11.
Angelini C, Fanin M. Limb girdle muscular dystrophies: clinical-genetical diagnostic update and prospects for therapy. Expert Opinion on Orphan Drugs. 2017;5:769–84.CrossRef
12.
Thompson R, Straub V. Limb-girdle muscular dystrophies - international collaborations for translational research. Nat Rev Neurol. 2016;12:294–309.CrossRefPubMed
13.
Paradas C, Llauger J, Diaz-Manera J, Rojas-García R, De Luna N, Iturriaga C, et al. Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies. Neurology. 2010;75:316–23.CrossRefPubMed
14.
Tian X, Liang WC, Feng Y, Wang J, Zhang VW, Chou CH, et al. Expanding genotype/phenotype of neuromuscular diseases by comprehensive target capture/NGS. Neurol Genet. 2015;1:e14.CrossRefPubMedPubMedCentral
15.
Stark Z, Schofield D, Alam K, Wilson W, Mupfeki N, Macciocca I, et al. Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement. Genet Med. 2017;19:867–74.CrossRefPubMed
16.
Yu M, Zheng Y, Jin S, Gang Q, Wang Q, Yu P, et al. Mutational spectrum of Chinese LGMD patients by targeted next-generation sequencing. PLoS One. 2017;12:e0175343.CrossRefPubMedPubMedCentral
17.
18.
Bing Q, Hu K, Tian Q, Zhao Z, Shen H, Li N, et al. Semi-quantitative assessment of lower limb MRI in dystrophinopathy. Int J Clin Exp Med. 2016;9:13723–32.
19.
20.
Spuler S, Carl M, Zabojszcza J, Straub V, Bushby K, Moore SA, et al. Dysferlin-deficient muscular dystrophy features amyloidosis. Ann Neurol. 2008;63:323–8.CrossRefPubMed
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.CrossRefPubMedPubMedCentral
31.
Jin SQ, Yu M, Zhang W, Lyu H, Yuan Y, Wang ZX. Dysferlin gene mutation spectrum in a large cohort of Chinese patients with dysferlinopathy. Chin Med J (Engl). 2016;129:2287–93.CrossRef
32.
Seong MW, Cho A, Park HW, Seo SH, Lim BC, Seol D, et al. Clinical applications of next-generation sequencing-based gene panel in patients with muscular dystrophy: Korean experience. Clin Genet. 2016;89:484–8.CrossRefPubMed
33.
Kawai H, Akaike M, Kunishige M, Inui T, Adachi K, Kimura C, et al. Clinical, pathological, and genetic features of limb-girdle muscular dystrophy type 2A with new calpain 3 gene mutations in seven patients from three Japanese families. Muscle Nerve. 1998;21:1493–501.CrossRefPubMed
34.
Chae J, Minami N, Jin Y, Nakagawa M, Murayama K, Igarashi F, et al. Calpain 3 gene mutations: genetic and clinico-pathologic findings in limb-girdle muscular dystrophy. Neuromuscul Disord. 2001;11:547–55.CrossRefPubMed
35.
Park HJ, Jang H, Lee JH, Shin HY, Cho SR, Park KD, et al. Clinical and pathological heterogeneity of Korean patients with CAPN3 mutations. Yonsei Med J. 2016;57:173–9.CrossRefPubMed
36.
Babameto-Laku A, Tabaku M, Tashko V, Cikuli M, Mokini V. The first case of primary alpha-sarcoglycanopathy identified in Albania, in two siblings with homozygous alpha-sarcoglycan mutation. Genet Couns. 2011;22:377–83.PubMed
37.
Ljunggren A, Duggan D, McNally E, Boylan KB, Gama CH, Kunkel LM, et al. Primary adhalin deficiency as a cause of muscular dystrophy in patients with normal dystrophin. Ann Neurol. 1995;38:367–72.CrossRefPubMed
38.
Duggan DJ, Gorospe JR, Fanin M, Hoffman EP, Angelini C. Mutations in the sarcoglycan genes in patients with myopathy. N Engl J Med. 1997;336:618–24.CrossRefPubMed
39.
Liang WC, Hayashi YK, Ogawa M, Wang CH, Huang WT, Nishino I, et al. Limb-girdle muscular dystrophy type 2I is not rare in Taiwan. Neuromuscul Disord. 2013;23:675–81.CrossRefPubMed
40.
Krahn M, Béroud C, Labelle V, Nguyen K, Bernard R, Bassez G, et al. Analysis of the DYSF mutational spectrum in a large cohort of patients. Human Mutat. 2009;30:E345–75.CrossRef
41.
Kergourlay V, Raï G, Blandin G, Salgado D, Béroud C, Lévy N, et al. Identification of splicing defects caused by mutations in the dysferlin gene. Hum Mutat. 2014;35:1532–41.CrossRefPubMed
42.
Punetha J, Kesari A, Uapinyoying P, Giri M, Clarke NF, Waddell LB, et al. Targeted re-sequencing emulsion PCR panel for myopathies: results in 94 cases. J Neuromuscul Dis. 2016;27:209–25.CrossRef
43.
Fu X, Yang H, Wei C, Jiao H, Wang S, Yang Y, et al. FKRP mutations, including a founder mutation, cause phenotype variability in Chinese patients with dystroglycanopathies. J Hum Genet. 2016;61:1013–20.CrossRefPubMed
44.
Mahmood OA, Jiang X, Zhang Q. Limb-girdle muscular dystrophy subtypes: first-reported cohort from northeastern China. Neural Regen Res. 2013;8:1907–18.PubMedPubMedCentral
45.
Nishikawa A, Mitsuhashi S, Miyata N, Nishino I. Targeted massively parallel sequencing and histological assessment of skeletal muscles for the molecular diagnosis of inherited muscle disorders. J Med Genet. 2017;54:104–10.CrossRefPubMed
46.
Voermans NC, Bonnemann CG, Hamel BCJ, Jungbluth H, van Engelen BG. Joint hypermobility as a distinctive feature in the differential diagnosis of myopathies. J Neurol. 2009;256:13–27.CrossRefPubMed
47.
Bugnitz CJ, Cripe LH, Lo WD, Flanigan KM. Recurrent fat embolic strokes in a patient with Duchenne muscular dystrophy with long bone fractures and a patent foramen Ovale. Pediatr Neurol. 2016;63:76–9.CrossRefPubMed
48.
Duncan DR, Kang PB, Rabbat JC, Briggs CE, Lidov HG, Darras BT, et al. A novel mutation in two families with limb-girdle muscular dystrophy type 2C. Neurology. 2006;67:167–9.CrossRefPubMed
49.
50.
Cyrulnik SE, Fee RJ, De Vivo DC, Goldstein E, Hinton VJ. Delayed developmental language milestones in children with Duchenne's muscular dystrophy. J Pediatr. 2007;150:474–8.CrossRefPubMedPubMedCentral
51.
Hackman P, Udd B, Bonnemann CG, Ferreiro A, Titinopathy Database Consortium. 219th ENMC International Workshop Titinopathies International database of titin mutations and phenotypes, Heemskerk, The Netherlands, 29 April-1 May 2016. Neuromuscul Disord. 2017;27:396–407.CrossRefPubMed
52.
De Cid R, Ben Yaou R, Roudaut C, Charton K, Baulande S, Leturcq F, et al. A new titinopathy: childhood-juvenile onset Emery-Dreifuss-like phenotype without cardiomyopathy. Neurology. 2015;85:2126–35.CrossRefPubMedPubMedCentral
53.
Jin S, Du J, Wang Z, Zhang W, Lv H, Meng L, et al. Heterogeneous characteristics of MRI changes of thigh muscles in patients with dysferlinopathy. Muscle Nerve. 2016;54:1072–9.CrossRefPubMed
54.
Kesper K, Kornblum C, Reimann J, Lutterbey G, Schroder R, Wattjes MP. Pattern of skeletal muscle involvement in primary dysferlinopathies: a whole-body 3.0-T magnetic resonance imaging study. Acta Neurol Scand. 2009;120:111–8.CrossRefPubMed
55.
ten Dam L, van der Kooi AJ, van Wattingen M, de Haan RJ, de Visser M. Reliability and accuracy of skeletal muscle imaging in limb-girdle muscular dystrophies. Neurology. 2012;79:1716–23.CrossRefPubMed
56.
Fischer D, Walter MC, Kesper K, Petersen JA, Aurino S, Nigro V, et al. Diagnostic value of muscle MRI in differentiating LGMD2I from other LGMDs. J Neurol. 2005;252:538–47.CrossRefPubMed
57.
Willis TA, Hollingsworth KG, Coombs A, Sveen ML, Andersen S, Stojkovic T, et al. Quantitative magnetic resonance imaging in limb-girdle muscular dystrophy 2I: a multinational cross-sectional study. PLoS One. 2014;9:e90377.CrossRefPubMedPubMedCentral
58.
Mercuri E, Pichiecchio A, Allsop J, Messina S, Pane M, Muntoni F. Muscle MRI in inherited neuromuscular disorders: past, present, and future. J Magn Reson Imaging. 2007;25:433–40.CrossRefPubMed
59.
Takahashi T, Aoki M, Tateyama M, Kondo E, Mizuno T, Onodera Y, et al. Dysferlin mutations in Japanese Miyoshi myopathy: relationship to phenotype. Neurology. 2003;60:1799–804.CrossRefPubMed
60.
Kergourlay V, Rai G, Blandin G, Salgado D, Béroud C, Lévy N, et al. Identification of splicing defects caused by mutations in the dysferlin gene. Hum Mutat. 2014;35:1532–41.CrossRefPubMed
61.
Allen-Brady K, Camp NJ. Genetic distance and markers used in linkage mapping. Methods Mol Biol. 2011;713:43–53.CrossRefPubMed
Metadata
Title
The clinical spectrum and genetic variability of limb-girdle muscular dystrophy in a cohort of Chinese patients
Authors
Liang Wang
Victor Wei Zhang
Shaoyuan Li
Huan Li
Yiming Sun
Jing Li
Yuling Zhu
Ruojie He
Jinfu Lin
Cheng Zhang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2018
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-018-0859-6

Other articles of this Issue 1/2018

Orphanet Journal of Rare Diseases 1/2018 Go to the issue

Letter to the Editor

TRAPPED - an insight into two sisters’ struggle to access treatment for a rare genetic disease

Research

Estrogen is involved in hemangioma regression associated with mast cells

Research

Emotional processes and stress in children affected by hereditary angioedema with C1-inhibitor deficiency: a multicenter, prospective study

Research

Fatal thoracic aortic aneurysm and dissection in a large family with a novel MYLK gene mutation: delineation of the clinical phenotype

Letter to the Editor

MicroRNAs are appropriate in mitochondrial related hearing loss? Answer to the skepticism

Research

White matter microstructural damage in early treated phenylketonuric patients